Table 1.
Specific measures for hepatitis C treatment in people who inject drugs and barriers observed in harm reduction services, as reported from 35 European countries
| Country | Specific for PWID | Barriers in HR services | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Linkage-to-care protocol | Treatment guidelines | Guidelines impact access to testing/treatment | Guidelines impact access to HR services | Discrepancy in DAA use between policy and practice | Automatic reimbursement of DAA | Lack of funding/political support/general recognition of HR | Shortage of know-ledge/training/skilful staff | Law | |
| Albania | Y | Y | Y | Y | Y | Y | Y | na | na |
| Austria | N | N/A | N/A | N/A | N | Y | na | na | na |
| Belgium | N | Y | Y | Y | N | Y | na | na | na |
| Bosnia and Hercegovina | na | N/A | N/A | N/A | N | Y | na | na | na |
| Bulgaria | N | N | Y | N | Y | Y | na | na | na |
| Croatia | Y | Y | Y | N | N | Y | na | na | na |
| CzechRepublic | N | Y | Y | Y | N | Y | na | Y | na |
| Denmark | na | N/A | N/A | N/A | N | Y | na | na | na |
| Finland | N | Y | Y | Y | Y | Y | na | na | na |
| France | Y | Y | Y | Y | N | Y | Y | Y | na |
| Georgia | Y | Y | Y | Y | N | Y | na | na | na |
| Germany | Y | Y | Y | Y | N | Y | Y | Y | na |
| Greece | Y | Y | Y | Y | N | Y | na | na | Y |
| Hungary | N | Y | Y | N | Y | N | Y | na | na |
| Ireland | N | Y | N | Y | N | Y | Y | Y | na |
| Italy | N | Y | N | N | N | Y | na | na | na |
| Latvia | Y | Y | MI | MI | N | Y | na | na | na |
| Luxembourg | Y | N/A | N/A | N/A | N | Y | na | na | na |
| Montenegro | Y | Y | Y | N | N | Y | na | na | Y |
| Macedonia, North | N | N/A | N/A | N/A | N/A | Y | Y | na | na |
| Netherlands | Y | N | Y | N | N | Y | na | na | na |
| Norway | Y | Y | Y | Y | N | Y | na | na | na |
| Poland | N | N/A | N/A | N/A | Y | Y | na | na | na |
| Portugal | Y | Y | Y | Y | N | Y | na | na | na |
| Romania | na | N | Y | Y | Y | N | Y | na | na |
| Russia | N | N | N | N | Y | Y | na | Y | na |
| Scotland | Y | Y | Y | N | N | Y | na | na | na |
| Serbia | Y | Y | N | N | Y | N | Y | na | na |
| Slovakia | N | N | N | N | Y | Y | na | na | na |
| Slovenia | Y | Y | Y | Y | N | Y | na | na | na |
| Spain | Y | Y | Y | Y | N | Y | na | na | na |
| Sweden | Y | Y | Y | Y | N | Y | na | na | na |
| Switzerland | N | Y | Y | Y | N | Y | na | na | na |
| Ukraine | Y | Y | Y | Y | Y | Y | na | na | na |
| UK | N | N | N | Y | N | N | Y | na | na |
Scotland was treated separately from the rest of the UK
N no, Y yes, na not analyzed, N/A not applicable because there are no national guidelines, DAA direct acting antivirals, HR harm reduction